Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096715 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
A Phase 1 study of Unresectable Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05096715: Recruiting Phase 1 study of Unresectable Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital.
NCT05096715 is a Phase 1 study of Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 85-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096715, a Phase 1 study of Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: * Atezolizumab * Bevacizumab * Stereotactic body radiation therapy (SBRT)
Primary Outcome
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- RADIATION Stereotactic body radiation therapy (SBRT)
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2032-01-31 |
| Phase | Phase 1 |
What NCT05096715 shows while recruiting
NCT05096715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 85-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05096715 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05096715 about?
NCT05096715 is a clinical study titled "Atezolizumab+Bevacizumab+SBRT in Unresectable HCC". This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: * Atezolizumab * Bevacizumab * Stereotactic b...
What is the current status of trial NCT05096715?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-08-23. Estimated completion is 2032-01-31.
What conditions does trial NCT05096715 study?
This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05096715?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Stereotactic body radiation therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT05096715?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096715 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05096715's enrollment target sits among peer trials
20 12th of 12 higher than 1 of 12 other Unresectable Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unresectable Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI